Compared with usual care, GLP-1 receptor agonists tirzepatide and semaglutide may be cost-effective options for patients with ...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% ...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% ...

Paris, France, Thursday, 18 September 2025) Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower ...

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes - helping stabilize blood glucose and lose ...

The competition to develop obesity treatments that are more convenient and powerful than Wegovy and Mounjaro is intensifying. Since the popularization ...

Annual Meeting 2025, held from August 29 to September 1 in Madrid, Spain, showcased a sweeping array of advancements in the ...

The rollout of antiretroviral therapy for HIV showed how global solidarity and smart policy can overcome barriers to new treatments, say Jirair Ratevosian and Jeffrey L Sturchio The arrival of ...

USA: Researchers have reported a potential risk of severe hypercalcemia when tirzepatide, a dual GIP and GLP-1 receptor ...

In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given ...